In addition, a patent was approved for the Israeli development for the treatment of headaches and neck pain
The Minister of Science, Yaakov Perry, is mobilizing to promote biomed in the Negev
The Minister of Science, Yaakov Perry, used the break between holidays for a meeting in order to promote the biomed field in the Negev. In favor of the issue, representatives of Bio-Negev, (a public utility company Ltd.), went to the minister's office to present to him the activity model that, in their estimation, will promote one of the economic fields that are developing these days in the Negev alongside high-tech.
"Bio-Negev is working to stabilize and condition the biotechnology industry in Israel, and the beginning of its activities is focused on the Negev, alongside the centers of excellence of Ben Gurion University, the National Institute of Biotechnology and Soroka University Medical Center," explained Bio-Negev's CEO, Dr. Inbar Freeman, and presented Bio-Negev's unique activity model, which is built from a cluster of companies working in cooperation to strengthen the cluster together and each individually. "The centers of excellence are an important anchor in the field of biotechnology in the Negev and the cluster is built around them. Bio-Negev recognizes the gap between these centers of excellence and the ability to bring excellent technologies to fruition. For this purpose, service companies operate in the cluster, which constitute the milestones in biotechnological development, and together, the cluster creates the envelope for young biotech companies, in the various stages of development," Dr. Freeman explained.
In the meeting with the minister, who showed great interest in the field of biotechnology that is developing in the Negev and in the Bio-Negev activity in particular and even promised to examine the issue of participation in the financing of the activity, the representatives of the partner organizations in the Bio-Negev participated: CEO of the commercialization company of Ben Gurion University in the Negev (BGN Technologies), Neta Cohen , the University's Vice President of Marketing, Sagi Langer, the CEO of Targets, Sima Kahlon, as well as the representative of the Development Authority The Negev, Vared Goshen. Bio-Negev founder and board member Dr. Shay Yarkoni and Dr. Freeman were also present at the meeting.
Bio-Negev, which is a global innovation center for the biotechnology and life sciences industry in the Negev, was established to serve as a 'super framework' for the development of the biotechnology and life sciences industry in the Negev region. The center combines existing resources and capabilities (academic, clinical and industrial), works to establish industrial infrastructures in the region and is a focal point that attracts financial, organizational, managerial and human resources to the Negev. Bio-Negev, which was established as a regional industrial "cluster", in the format of the European clusters (Bioclusters), is currently the only full member from Israel within the super-European framework - the European Council for Regional Biotechnology Centers - CEBR.
A grant of up to NIS 6 million to establish a laboratory complex for biotechnology companies in Jerusalem
The Jerusalem Development Authority, through the Bio-Jerusalem project, published a tender for the construction of a laboratory complex in Jerusalem intended for rent by start-up companies in the field of biomed. As part of the operations of the Jerusalem Development Authority, the Ministry for Jerusalem and the Diaspora and the Jerusalem Municipality to develop the biomed industry in the capital, the Jerusalem Development Authority is offering a precedent grant of up to NIS 6 million for the construction of a 1000 square meter chemistry and biology laboratory complex and offices. The grant, which joins a series of programs and benefits that exist in Jerusalem in the field The biomed is intended for entrepreneurs and property owners who will build and operate the complex, And they will rent space to biotechnology companies.
Moti Hazan, CEO of the Jerusalem Development Authority predicts that this initiative will be another magnet for biomed companies to Jerusalem "We offer a solution for a real need that currently exists in the biomed industry, which is numerous in start-up companies that do not manage to build research and development laboratories. This benefit joins a series of benefits that we recently launched that support the biomed industry, including the grant to encourage the absorption of employees in biomed companies which can reach up to 3.9 million NIS for the company, a grant for the purchase and construction of equipment and infrastructure for use by the industry which can reach 8 million NIS, a grant for the company Biomed moving to Jerusalem or expanding there and a grant for employing students in Biomed companies - all measures designed to encourage the activity of companies Biotechnology in the city."
"Since the launch of the Marom program, which is shared with the Ministry for Jerusalem and the Diaspora, the Jerusalem Municipality and the Jerusalem Development Authority, in which we significantly increased the unique benefits for Biomed companies, we have witnessed the growth of the sector in the city, which is reflected in the move of companies to Jerusalem, the expansion of existing companies and the establishment of new companies in the city. We encourage companies established and young biomeds, industry service providers and entrepreneurs in the field of life sciences to contact us to benefit from the wide basket of The benefits for companies operating in Jerusalem," added Mr. Hazan.
The start-up companies that require a laboratory infrastructure do not currently have an available and accessible solution. They can bear the cost of building the laboratory themselves or pay indirectly for the construction cost through a high rent and a long-term lease commitment. In both cases, most of the young companies do not have the required resources, and are therefore forced to work from within the academy or find creative solutions such as subletting or working with external contractors. The proposed solution, where companies will be able to rent laboratory space and offices for short or long periods, is unique in Israel and is based on similar models in the US and Europe. The model is flexible and modular, so that it allows for changes or replacement of tenants in the future.
The grant was given as part of the Marom Program, a multi-year plan to strengthen the economy of Jerusalem approved by the Israeli government in 2011, and which allocates over NIS 70 million to research and development and industry in the field of biotechnology in the capital between 2011-2016 for the purpose of strengthening Jerusalem as a biotechnological center.
A patent was approved for an Israeli development for the treatment of headaches and neck pain
The Israeli company Headway from the Trendlines Group, reports that it has received patent approval in the USA for a facility for the treatment of chronic neck and headache pain. The Occiflex, a dynamic cradle for the treatment of head and neck pain, is equipped with a unique mechanism that allows controlled maneuvering of the treated limb, thus providing the therapist with treatment options that were not possible until today The scope of the initial market in the US is estimated at 368 million dollars
Chronic head and neck pain, with a component of neck muscle abnormalities, affects the lives of hundreds of millions worldwide, treated in approximately 50,000 physical therapy and pain clinics. With the advancement of medicine and the increase in life expectancy, the number of people who regularly suffer from the problem also increases steadily. The treatment offered today, which includes drugs, invasive procedures and alternative solutions, is in many cases ineffective, ineffective in the long term, and also causes many side effects.
These days, Headway received a product patent in the USA and a pre-production series of the treatment bed with the dynamic cradle (Occiflex) will enter clinical trials later this year, after two years of research and development in collaboration with the Dutch company Enraf-Nonius. The company expects to start sales in less than a year, based on The international marketing channels of Enraf-Nonius. The scope of the initial American market is estimated at 368 million dollars.
Tamir Levital, CEO of Headway: "The initial idea for the development of the crib came from the long-standing frustration of Dr. Yaron River - a pain specialist, which resulted from a lack of effective treatment methods for head and neck pain. Today, there is a growing population of people suffering from these pains, with many What is missing is an effective, personal, safe, non-invasive and non-medicinal solution. During the R&D, we put emphasis on keeping the treatment environment as similar as possible which can be given to the manual treatment given today. This treatment, as effective as it may be, requires valuable time and physical effort from the therapist, and in fact cannot be performed beyond a few minutes. The ability of the device to repeatedly, accurately and conveniently perform the treatment that is tailored to the patient personally, for an unlimited time, at very low speeds, achieves excellent clinical results, as proven in 4 clinical trials carried out in recent years. Now, after the patent procedure for the product has been completed, we hope that in the near future OcciflexTM will take its natural place as a standard treatment for those suffering from head and neck pain."
